 |
Prospector
Profile
07.1387
|
| |
| CuraTech Industries, Inc. |
NAICS |
325412 |
| 6337 Highland Drive, Suite 1053
Salt Lake City, UT 84121 |
Description |
Health Supplements Mfg. |
| (801) 616-2355 |
Employees |
3 |
|
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-0.6270 |
| |
Assets |
(mil) |
0.0530 |
| |
Liability |
(mil) |
0.0060 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
CuraTech Industries, Inc. had a $107,130 net loss for the three months ended June 30, 2007, lower than the $483,427 net loss incurred during the second quarter of 2006. For the six months ended June 30, 2007, the Company had a $189,682 net loss, lower than the $483,427 net loss incurred during the first half of 2006. As of June 30, 2007, the Company's balance sheet showed an accumulated deficit of $770,315.
|
| |
|
Intellectual Property:
The Company's MedaCure International, Inc. subsidiary does not presently have any patents related to its product. However, MedaCure intends to aggressively defend and expand its intellectual property and technology by applying for patent and/or copyright protection in the future. MedaCure also intends to rely on trade secrets, common law trademark rights and trademark registrations, and will continue to protect its intellectual property via non-disclosure agreements, license agreements and limited information distribution. [SEC Filing 10-KSB 04-17-07]
|
| |
|
Description:
The Company engages in the acquisition, development, and marketing of a health supplement for enhancing and building-up the body's natural immune system defenses in humans and animals.
|
| |
|
Officers:
Lincoln Dastrup (CEO, CFO & Dir.); Jarom Dastrup (EVP, Sec. & Dir.); Linda L. Dastrup (Treas. & Dir.)
|
| |
|
Auditor:
Moore & Associates Chartered
|
| |
|
Securities:
Common Stock-Symbol CUTC.OB; OTC BB;
15,912,387 common shares outstanding as of June 30, 2007.
|
| |
| |
| |
| return to main page |
|
|
